Ourotech Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Out of Business

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Liquidation

Ourotech General Information

Description

Developer of advanced cancer diagnostic technology designed to improve treatment selection through personalized tumor modeling. The company platform offers microfluidic devices and biomimetic platforms that replicate tumor microenvironments, enabling precise drug screening and response analysis, allowing oncologists and researchers to identify effective therapies tailored to individual patient tumor profiles, enhancing precision in cancer care.

Contact Information

Website
www.ourotech.ca
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Prospect House
  • Rouen Road
  • London NR1 1RE
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Big Data, Artificial Intelligence & Machine Learning, HealthTech, Life Sciences, Oncology
Corporate Office
  • Prospect House
  • Rouen Road
  • London NR1 1RE
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ourotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Bankruptcy: Liquidation 21-Aug-2025 Completed Out of Business
9. Later Stage VC Completed Pre-Clinical Trials
8. Accelerator/Incubator Completed Pre-Clinical Trials
7. Seed Round 29-Oct-2021 Completed Pre-Clinical Trials
6. Accelerator/Incubator 19-Oct-2021 Completed Startup
5. Angel (individual) 03-Mar-2020 Completed Startup
4. Accelerator/Incubator 15-Jan-2019 Completed Startup
3. Accelerator/Incubator 31-Mar-2017 Completed Startup
2. Accelerator/Incubator 10-Jun-2015 $32.7K $32.7K Completed Startup
1. Grant 11-May-2015 $55K Completed Startup
To view Ourotech’s complete valuation and funding history, request access »

Ourotech Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed-5
Seed-4
Seed-3
Seed-2 1,775,956 $0.000010 8% $0.07 $0.07 1x $0.07 7.3%
Seed-1 7,307,114 $0.000010 8% $0.46 $0.46 1x $0.46 28.59%
To view Ourotech’s complete cap table history, request access »

Ourotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of advanced cancer diagnostic technology designed to improve treatment selection through personalized tumor mo
Drug Discovery
London, United Kingdom
7 As of 2026

Salt Lake City, UT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ourotech Competitors (1)

One of Ourotech’s competitors is Recursion Pharmaceuticals, a Formerly VC-backed company based in Salt Lake City, UT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Recursion Pharmaceuticals Formerly VC-backed Salt Lake City, UT
You’re viewing 1 of 1 competitors. Get the full list »

Ourotech Patents

  • 20

    Total Documents Applications and Grants

  • Total Patents Families

  • 11

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

Ourotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026092611-A1 Cyclin dependent kinase 12 (cdk12) small molecules inhibitors Pending 31-Oct-2024
EP-4573515-A1 Methods of forming patient-derived 3d cell cultures for tracking live immune-tumor interactions Pending 16-Aug-2022
EP-4573515-A4 Methods of forming patient-derived 3d cell cultures for tracking live immune-tumor interactions Pending 16-Aug-2022
US-20260056187-A1 Methods of forming patient-derived 3d cell cultures for tracking live immune-tumor interactions Pending 16-Aug-2022
WO-2024039744-A1 Methods of forming patient-derived 3d cell cultures for tracking live immune-tumor interactions Inactive 16-Aug-2022 G01N33/5082
To view Ourotech’s complete patent history, request access »

Ourotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Ourotech FAQs

  • When was Ourotech founded?

    Ourotech was founded in 2015.

  • Where is Ourotech headquartered?

    Ourotech is headquartered in London, United Kingdom.

  • What is the size of Ourotech?

    Ourotech has 7 total employees.

  • What industry is Ourotech in?

    Ourotech’s primary industry is Drug Discovery.

  • Is Ourotech a private or public company?

    Ourotech is a Private company.

  • What is Ourotech’s current revenue?

    The current revenue for Ourotech is .

  • How much funding has Ourotech raised over time?

    Ourotech has raised $4.68M.

  • Who are Ourotech’s competitors?

    Recursion Pharmaceuticals is a competitor of Ourotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process